We are live on ! Find out more
PBE icon

Invesco Biotechnology & Genome ETF
PBE

69 hedge funds and large institutions have $52.3M invested in Invesco Biotechnology & Genome ETF in 2017 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 4

15% more funds holding

Funds holding: 60 → 69 (+9)

1.14% more ownership

Funds ownership: 21.02% → 22.16% (+1.1%)

5% less capital invested

Capital invested by funds: $55M → $52.3M (-$2.71M)

13% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 16

Holders
69
Holders Change
+9
Holders Change %
+15%
% of All Funds
1.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
14
Reduced
16
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$2.11M
2
Citadel Advisors
Citadel Advisors
Florida
+$398K
3
LTFS
Ladenburg Thalmann Financial Services
Florida
+$316K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$230K
5
BTS
BB&T Securities
Virginia
+$225K

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$1.71M
2
RJFSA
Raymond James Financial Services Advisors
Florida
-$544K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$522K
4
Goldman Sachs
Goldman Sachs
New York
-$256K
5
TSS
Two Sigma Securities
New York
-$226K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIP
51
Ameritas Investment Partners
Nebraska
$30K – – –
Manulife (Manufacturers Life Insurance)
52
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$28K – – –
CA
53
Calton & Associates
Florida
$28K +$25.5K +544 New
APA
54
American Portfolios Advisors
New York
$24.8K +$24.6K +525 New
FANJ
55
Financial Architects (New Jersey)
New Jersey
$24K – – –
FAAS
56
First Allied Advisory Services
California
$24K +$24.9K +531 New
Carson Wealth (CWM LLC)
57
Carson Wealth (CWM LLC)
Nebraska
$20K – – –
IWM
58
IHT Wealth Management
Illinois
$16K – – –
RFA
59
Reilly Financial Advisors
California
$14K – – –
KJWM
60
Kiley Juergens Wealth Management
Washington
$14K +$14.1K +300 New
CAPTRUST Financial Advisors
61
CAPTRUST Financial Advisors
North Carolina
$12K – – –
PNC Financial Services Group
62
PNC Financial Services Group
Pennsylvania
$10K – – –
ME
63
McIlrath & Eck
Washington
$10K +$9.61K +205 New
AIM
64
Advantage Investment Management
Iowa
$9K – – –
HWM
65
Holloway Wealth Management
Florida
$9K – – –
ASN
66
Advisory Services Network
Georgia
$8K +$4.78K +102 +138%
GFP
67
Gryphon Financial Partners
Ohio
$7K +$7.41K +158 New
WAM
68
Wealthspire Advisors (Maryland)
Maryland
$5K – – –
RFC
69
Regions Financial Corp
Alabama
$1K +$1.27K +27 New
Goldman Sachs
70
Goldman Sachs
New York
– -$256K -5,120 Closed
TSS
71
Two Sigma Securities
New York
– -$226K -4,522 Closed
NFG
72
Next Financial Group
Texas
– -$67K -1,350 Closed
JP Morgan Chase
73
JP Morgan Chase
New York
– -$4K -82 Closed
1 2
3

PBE Hedge Fund Activity: Q4 2017 in Review

69 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q4 2017, worth a combined $52.3M — down 4.9% from $55M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new PBE positions and 4 closed out — a net gain of 9 holders — while 14 added to existing stakes and 16 trimmed.

The largest buyer was Virtu Financial, adding an estimated $2.11M. The largest seller was Bank of America, cutting an estimated $1.71M.

  • 69 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q4 2017, up from 60 in Q3 2017.
  • Funds reported $52.3M of Invesco Biotechnology & Genome ETF stock for Q4 2017, down 4.9% quarter-over-quarter.
  • 13 funds opened new Invesco Biotechnology & Genome ETF positions in Q4 2017 and 4 closed out, a net change of +9 holders.
  • The largest Invesco Biotechnology & Genome ETF buyer in Q4 2017 was Virtu Financial, an estimated $2.11M added.
  • The largest Invesco Biotechnology & Genome ETF seller in Q4 2017 was Bank of America, an estimated $1.71M sold.

Based on aggregated 13F filings for Q4 2017.